MXPA04002249A - Preparacion y uso de derivados de 1,5,6,7,-tetrahidro-pirrolo[3,2-c]piridina para el tratamiento de la obesidad. - Google Patents

Preparacion y uso de derivados de 1,5,6,7,-tetrahidro-pirrolo[3,2-c]piridina para el tratamiento de la obesidad.

Info

Publication number
MXPA04002249A
MXPA04002249A MXPA04002249A MXPA04002249A MXPA04002249A MX PA04002249 A MXPA04002249 A MX PA04002249A MX PA04002249 A MXPA04002249 A MX PA04002249A MX PA04002249 A MXPA04002249 A MX PA04002249A MX PA04002249 A MXPA04002249 A MX PA04002249A
Authority
MX
Mexico
Prior art keywords
alkyl
optionally substituted
alkoxy
trifluoromethyl
halogen
Prior art date
Application number
MXPA04002249A
Other languages
English (en)
Spanish (es)
Inventor
J O'connor Stephen
Original Assignee
Bayer Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharmaceuticals Corp filed Critical Bayer Pharmaceuticals Corp
Publication of MXPA04002249A publication Critical patent/MXPA04002249A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Addiction (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MXPA04002249A 2001-09-24 2002-09-24 Preparacion y uso de derivados de 1,5,6,7,-tetrahidro-pirrolo[3,2-c]piridina para el tratamiento de la obesidad. MXPA04002249A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32444301P 2001-09-24 2001-09-24
PCT/US2002/030541 WO2003027114A1 (en) 2001-09-24 2002-09-24 Preparation and use of 1,5,6,7-tetrahydropyrrolo[3,2-c]pyridine derivatives for treatment of obesity

Publications (1)

Publication Number Publication Date
MXPA04002249A true MXPA04002249A (es) 2004-06-29

Family

ID=23263607

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04002249A MXPA04002249A (es) 2001-09-24 2002-09-24 Preparacion y uso de derivados de 1,5,6,7,-tetrahidro-pirrolo[3,2-c]piridina para el tratamiento de la obesidad.

Country Status (9)

Country Link
US (2) US7071207B2 (https=)
EP (1) EP1432708B1 (https=)
JP (1) JP2005504100A (https=)
AT (1) ATE311386T1 (https=)
CA (1) CA2461142A1 (https=)
DE (1) DE60207744T2 (https=)
ES (1) ES2252524T3 (https=)
MX (1) MXPA04002249A (https=)
WO (1) WO2003027114A1 (https=)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3813152B2 (ja) 2002-03-12 2006-08-23 メルク エンド カムパニー インコーポレーテッド 置換アミド類
EP1558252B1 (en) 2002-08-02 2007-10-10 Merck & Co., Inc. Substituted furo [2,3-b]pyridine derivatives
US7129239B2 (en) 2002-10-28 2006-10-31 Pfizer Inc. Purine compounds and uses thereof
US7247628B2 (en) 2002-12-12 2007-07-24 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
CN101012193A (zh) 2003-01-02 2007-08-08 霍夫曼-拉罗奇有限公司 新cb 1受体反激动剂
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7329658B2 (en) 2003-02-06 2008-02-12 Pfizer Inc Cannabinoid receptor ligands and uses thereof
US7176210B2 (en) 2003-02-10 2007-02-13 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US7145012B2 (en) 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US7141669B2 (en) 2003-04-23 2006-11-28 Pfizer Inc. Cannabiniod receptor ligands and uses thereof
US7268133B2 (en) 2003-04-23 2007-09-11 Pfizer, Inc. Patent Department Cannabinoid receptor ligands and uses thereof
US7232823B2 (en) 2003-06-09 2007-06-19 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
WO2005007628A1 (en) 2003-07-11 2005-01-27 Bristol-Myers Squibb Company Tetrahydroquinoline derivatives as cannabinoid receptor modulators
JP2007501827A (ja) * 2003-08-08 2007-02-01 ファルマシア・イタリア・エス・ピー・エー キナーゼ阻害剤として活性なピリミジルピロール誘導体
US20050043346A1 (en) * 2003-08-08 2005-02-24 Pharmacia Italia S.P.A. Pyridylpyrrole derivatives active as kinase inhibitors
US7326706B2 (en) 2003-08-15 2008-02-05 Bristol-Myers Squibb Company Pyrazine modulators of cannabinoid receptors
US7151097B2 (en) 2003-11-07 2006-12-19 Pfizer Inc. Bicyclic pyrazolyl and imidazolyl compounds and uses thereof
EP1734963A4 (en) 2004-04-02 2008-06-18 Merck & Co Inc METHOD FOR TREATING PEOPLE WITH METABOLIC AND ANTHROPOMETRIC DISORDER
TW200602314A (en) 2004-05-28 2006-01-16 Tanabe Seiyaku Co A novel pyrrolidine compound and a process for preparing the same
CA2613678A1 (en) 2005-06-02 2006-12-07 Glenmark Pharmaceuticals S.A. Novel cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
US7923465B2 (en) 2005-06-02 2011-04-12 Glenmark Pharmaceuticals S.A. Cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
AR056560A1 (es) 2005-10-06 2007-10-10 Astrazeneca Ab Pirrolopiridinonas como moduladores cb1
US7618982B2 (en) 2005-12-19 2009-11-17 Nerviano Medical Sciences S.R.L. Heteroarylpyrrolopyridinones active as kinase inhibitors
CN101007815B (zh) * 2006-01-27 2010-06-23 江苏恒瑞医药股份有限公司 吡咯并六元杂环化合物及其在医药上的用途
DK1973910T3 (da) 2006-01-27 2013-08-12 Shanghai Hengrui Pharm Co Ltd Pyrrolo[3,2-c]pyridin-4-on-2-indolinon-proteinkinaseinhibitorer
ES2546816T3 (es) 2007-02-27 2015-09-28 Nerviano Medical Sciences S.R.L. Isoquinolinpirrolopiridinonas activas como inhibidores de cinasa
AR065909A1 (es) * 2007-04-03 2009-07-08 Astrazeneca Ab Agentes terapeuticos 685
AR066207A1 (es) * 2007-04-03 2009-08-05 Astrazeneca Ab Agentes terapeuticos 684
WO2008134354A1 (en) * 2007-04-27 2008-11-06 Array Biopharma, Inc. TNF-α PRODUCTION INHIBITOR
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
MX354786B (es) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
EP2003129B1 (en) 2007-06-11 2017-08-09 Nerviano Medical Sciences S.r.l. 1H-Pyrido[3,4-B]indol-1-one and 2,3,4,9-Tetrahydro-1H-Beta-Carbolin-1-one Derivatives
ES2522968T3 (es) 2008-06-04 2014-11-19 Synergy Pharmaceuticals Inc. Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
AU2009270833B2 (en) 2008-07-16 2015-02-19 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
EP2348857B1 (en) 2008-10-22 2016-02-24 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US8329914B2 (en) 2008-10-31 2012-12-11 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
JP2013520502A (ja) 2010-02-25 2013-06-06 メルク・シャープ・エンド・ドーム・コーポレイション 有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
SG192941A1 (en) 2011-02-25 2013-09-30 Merck Sharp & Dohme Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
RU2015106909A (ru) 2012-08-02 2016-09-27 Мерк Шарп И Доум Корп. Антидиабетические трициклические соединения
KR20150118158A (ko) 2013-02-22 2015-10-21 머크 샤프 앤드 돔 코포레이션 항당뇨병 비시클릭 화합물
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
AU2014235215A1 (en) 2013-03-15 2015-10-01 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
AU2014235209B2 (en) 2013-03-15 2018-06-14 Bausch Health Ireland Limited Guanylate cyclase receptor agonists combined with other drugs
BR112015030326A2 (pt) 2013-06-05 2017-08-29 Synergy Pharmaceuticals Inc Agonistas ultrapuros de guanilato ciclase c, método de fabricar e usar os mesmos
EP3033342A1 (en) * 2013-08-13 2016-06-22 Grünenthal GmbH Annelated pyrroles and their use as crac inhibitors
JO3442B1 (ar) 2013-10-07 2019-10-20 Takeda Pharmaceuticals Co مضادات ذات نوع فرعي من مستقبل سوماتوستاتين 5 (sstr5)
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
US11072602B2 (en) 2016-12-06 2021-07-27 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1484140A (en) 1974-04-24 1977-08-24 Wyeth John & Brother Ltd Pyrrolopyridine derivatives
US4897390A (en) * 1987-07-21 1990-01-30 Ruhe Rodney C Novel anti-obesity compounds and method of use
KR960705824A (ko) * 1993-10-20 1996-11-08 아사이 이페이 인돌 유도체(Indole Derivative)
KR100251522B1 (ko) * 1997-08-13 2000-08-01 김충섭 할로알콕시기를 함유하는 피롤[3,2-c]퀴놀린 유도체 및 약학적으로 허용되는 그의 염
ATE328887T1 (de) 1999-01-19 2006-06-15 Neurosearch As Kondensierte heterocyclische verbindungen und ihre verwendung zur behandlung von neurodegenerativen erkrankungen
CA2376158C (en) 1999-07-06 2011-03-15 Endorecherche, Inc. Use of selective estrogen receptor modulators in the manufacture of medicaments for treating and/or suppressing weight gain

Also Published As

Publication number Publication date
JP2005504100A (ja) 2005-02-10
EP1432708B1 (en) 2005-11-30
US20040224970A1 (en) 2004-11-11
ES2252524T3 (es) 2006-05-16
DE60207744T2 (de) 2006-08-03
DE60207744D1 (de) 2006-01-05
CA2461142A1 (en) 2003-04-03
US20060122215A1 (en) 2006-06-08
ATE311386T1 (de) 2005-12-15
WO2003027114A1 (en) 2003-04-03
US7071207B2 (en) 2006-07-04
EP1432708A1 (en) 2004-06-30

Similar Documents

Publication Publication Date Title
MXPA04002249A (es) Preparacion y uso de derivados de 1,5,6,7,-tetrahidro-pirrolo[3,2-c]piridina para el tratamiento de la obesidad.
TWI901639B (zh) 雜環glp-1促效劑
US20040267028A1 (en) Preparation and use of pyrrole derivatives for treating obesity
RU2769448C2 (ru) Новые пиразолпиримидиновые производные
US20050256167A1 (en) Preparation and use of imidazole derivatives for treatment of obesity
KR101991327B1 (ko) 오피오이드 수용체 리간드와 그 용도 및 제조방법
ES2256560T3 (es) Heterociclos de 5 mienbros que contienen nitrogeno sustituidos con felino para el tratamiento de la obesidad.
US9732075B2 (en) Benzimidazole-proline derivatives
EP2516439B1 (en) Diaza-spiro[5.5]undecanes as orexin receptor antagonists
JP6716711B2 (ja) Apjアゴニストとしての6−ヒドロキシ−4−オキソ−1,4−ジヒドロピリミジン−5−カルボキシアミド
EA022409B1 (ru) Производные 5,6-дигидроимидазо[1,2-а]пиразин-8-иламина, пригодные в качестве ингибиторов бета-секретазы (васе)
KR20160013149A (ko) 디히드로피리디논 mgat2 억제제
WO2004050651A1 (en) Anilinopyrazole derivatives useful for the treatment of diabetes
JP2018052818A (ja) スルホンアミド化合物
CN110452235B (zh) 一类含氟异噁唑类化合物及其制备方法、药物组合物和用途
WO2005112923A2 (en) 5-anilino-4-heteroarylpyrazole derivatives useful for the treatment of diabetes
KR20100088695A (ko) 거울상 이성질체가 강화된 이미다조아제피논 화합물
WO2010141690A2 (en) Indane analogs and use as pharmaceutical agents and process of making
US20110112133A1 (en) Dihydro pyrroloquinoline derivatives
HK40083559A (en) Heterocyclic glp-1 agonists
AU2002343423A1 (en) Imidazole-4-carboxamide derivatives, preparation and use thereof for treatment of obesity

Legal Events

Date Code Title Description
FG Grant or registration